Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 13,27 € (-3,35%). La mediana è 14,59 € (+6,26%).
| Acquista |
8 |
| Mantieni |
16 |
| Vendi |
2 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Avantor's strong Q2 figures and raised full-year outlook lift stock
Avantor beat analyst estimates in the second quarter on both revenue (USD 1.69 billion) and adjusted diluted EPS (USD 0.21). Management raised the full-year guidance for adjusted EPS to USD 0.80–0.83, which fueled the premarket price move. The positive reaction is seen as a sign that the restructuring program "Revival" is delivering initial financial improvements; the stock was trading at USD 13.00, still below its 52-week high. » Altro su de.investing.com
Avantor gains traction under new management as stabilization begins
Longleaf Partners highlighted Avantor as a contributor in Q2 2026, noting signs of stabilization and new CEO Emmanuel Ligner's guidance for revenue growth and strong free cash flow generation in 2H26. Book-to-bill exceeded one and management has progressed on operational initiatives, including a redesigned VWR website and improved ship-to-order patterns in Bioprocessing. Avantor closed at $10.39 on July 10, has a market cap of $7.09 billion, and has seen mixed recent performance with a one-month gain but a large 52-week decline. » Altro su finance.yahoo.com
Avantor names Ludovic Brellier EVP of Bioscience & Medtech Products and chief transformation officer
Avantor appointed Ludovic Brellier as Executive Vice President of Bioscience & Medtech Products and Chief Transformation Officer, effective May 1. Brellier will run growth and operations for the BMP business and lead the enterprise-wide Revival Management Office, drawing on his prior leadership at Danaher and Cytiva. Benoit Gourdier will remain through end of 2026 to ensure an orderly transition, and CEO Emmanuel Ligner said Brellier’s transformation experience will support the company’s strategic initiatives. » Altro su finance.yahoo.com
Avantor: insider buying continues streak as life‑sciences industry reports net selling in Q1
A Barclays analysis shows that insiders in the life‑sciences and diagnostics industry sold shares totaling USD 187m in Q1/2026. Avantor led open‑market purchases (around USD 2.4m), marking its fourth consecutive quarter of insider buying. Natera reported mostly preplanned sales of about USD 123m; Medpace, Guardant Health and Twist were among the largest open‑market sellers. Overall, open‑market purchases of USD 2.9m were matched against sales of USD 33m. » Altro su de.investing.com
Avantor appoints Ludovic Brellier as EVP and chief transformation officer
Avantor will appoint Ludovic Brellier as of May 1 as executive vice president for Bioscience & Medtech Products and chief transformation officer. He will take over the BMP business and lead the Revival Management Office, brings experience from Danaher/Cytiva and is expected to drive company-wide transformation and integration initiatives. Benoit Gourdier will remain with the company until no later than the end of 2026 to support the transition. The personnel move comes against the backdrop of a share price of $7.26 near its 52-week low, a six-month loss of 46% and analysts’ expectations of a return to profitability this year. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 1,5 Mld | 8,36% |
| Utile lordo | 472,15 Mln | 5,24% |
| Utile netto | 179,57 Mln | 129,61% |
| EBITDA | 214,71 Mln | 146,59% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 9,38 Mld € |
Numero di azioni | 677,62 Mln |
Massimo/minimo a 52 settimane | 15,92 € - 6,63 € |
| Dividendi | No |
Beta | 0,95 |
Rapporto P/E | 30,29 |
Rapporto PEG | -0,02 |
Rapporto P/B | 1,76 |
Rapporto P/S | 1,55 |
Profilo aziendale
Avantor, Inc. fornisce prodotti e servizi a clienti nei settori biofarmaceutico, sanitario, dell'istruzione e della pubblica amministrazione, delle tecnologie avanzate e dei materiali applicati, nelle Americhe, in Europa, in Asia, in Medio Oriente e in Africa. L'azienda offre materiali e materiali di consumo, come sostanze chimiche di elevata purezza e reagenti, prodotti e forniture per laboratorio, materiali in silicone formulati, eccipienti personalizzati, assemblaggi monouso personalizzati, resine e colonne per cromatografia di processo, kit per la preparazione di campioni analitici, prodotti per l'istruzione e la microbiologia, kit per studi clinici, pompe peristaltiche e puntali per la movimentazione di fluidi. Fornisce inoltre apparecchiature e strumentazione, tra cui sistemi di filtrazione, sistemi per l'inattivazione virale, incubatori, strumenti analitici, evaporatori, congelatori ultra-freddi, cabine di sicurezza biologica e forniture per ambienti critici. Inoltre, l'azienda offre servizi e approvvigionamenti specialistici, comprendenti servizi in loco per laboratori e produzione, servizi clinici, per le apparecchiature, di approvvigionamento e sourcing, e servizi di scale-up e sviluppo di materiali biofarmaceutici. Avantor, Inc. è stata fondata nel 1904 ed ha sede a Radnor, in Pennsylvania.
| Nome | Avantor |
| CEO | Emmanuel Ligner |
| Sede centrale | Radnor,
pa Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Strumenti e servizi per le scienze della vita |
| Quotazione in borsa | 17/05/2019 |
| Dipendenti | 13.500 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NYSE | AVTR |
Frankfurt | AVG.F |
Düsseldorf | AVG.DU |
SIX | AVG.SW |
München | AVG.MU |
Wien | AVTR.VI |